Explain this page
Arphra AIPlain-English read on Cytokinetics, Incorporated’s valuation06-17today
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6d
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6d
- Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?6d
- Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript15d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2.86
-96.43% vs spot
Recommendation
Sell
3 of 4 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $107.11 (+33.87%)
Candlestick · 1Y
Open in chart workstation →CYTK
78.78+20.90%H 80.15L 58.43MA50 68.87MA200 —Avg vol 2.1M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.06% | +0.01% | +3.99% | +33.31% | +24.66% | +25.92% | +139.55% | +142.90% | +254.81% | +785.07% | -17.17% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$79.50
Bid
$76.20
200 sh
Ask
$81.00
20 sh
Spread
$4.800
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $17.76M | -$183.03M | $-1.50 |
| Q3 Sep 2025 | $1.94M | -$306.18M | $-2.55 |
| Q2 Jun 2025 | $66.77M | -$134.37M | $-1.12 |
| Q1 Mar 2025 | $1.58M | -$161.38M | $-1.36 |
| Q4 Dec 2024 | $16.93M | -$150.02M | $-1.27 |
| Q3 Sep 2024 | $463K | -$160.55M | $-1.36 |
Sector & industry today
LiveSectors
- Real Estate+1.01%
- Consumer Cyclical+0.94%
- Energy+0.84%
- Consumer Defensive+0.82%
- Financial Services+0.23%
- Basic Materials-0.11%
- Healthcare-0.18%
- Communication Services-0.18%
- Industrials-0.47%
- Technology-0.85%
- Utilities-1.03%
Top industries (issuer's industry highlighted)
- Biotechnology+3.28%
- Software - Services+9.60%
- Broadcasting+8.34%
- Travel Services+7.87%
- Computer Hardware+4.56%
- Oil & Gas Energy-3.54%
- Electrical Equipment & Parts-3.26%
- Semiconductors-2.12%
- Communication Equipment+2.06%
- REIT - Healthcare Facilities+2.01%
- Drug Manufacturers - Specialty & Generic+1.99%
- Consulting Services-1.97%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·Jun 17, 2026
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·Jun 17, 2026
- Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?zacks.com·Jun 17, 2026
- Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Cytokinetics Announces Call for Proposals for Annual Corporate Giving Programglobenewswire.com·Jun 08, 2026
- Cytokinetics Announces Call for Proposals for Annual Corporate Giving Programglobenewswire.com·Jun 08, 2026
- Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?zacks.com·Jun 04, 2026
- Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conferenceglobenewswire.com·May 12, 2026
Recent analyst activity
DB- Jun 17, 2026GradeOutperform → OutperformRBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'RBC Capital
- Jun 17, 2026PT$119.00RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'RBC Capital
Peers
No peer list available for CYTK.
Total assets
$1.42B
Total debt
$1.28B
Cash & equiv
$882.22M
Operating CF
-$510.01M
Free cash flow
-$534.82M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $88.04M | -$612.26M | -$784.96M | $-6.54 | -891.60% |
| FY 2024 | $18.47M | -$536.25M | -$589.53M | $-5.26 | -3191.11% |
| FY 2023 | $7.53M | -$496.21M | -$526.24M | $-5.45 | -6988.63% |
| FY 2022 | $94.59M | -$324.2M | -$388.96M | $-4.33 | -411.21% |
| FY 2021 | $70.43M | -$186.31M | -$215.31M | $-2.80 | -305.72% |